Non-small cell lung cancer
Conditions
Interventions
Combination therapy of afatinib + bevacizumab
Sponsors
Juntendo University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically or cytologically proven non-small cell lung cancer 2)Harboring sensitive EGFR mutation 3)Stage IIIB, IV, relapse post operation and no indication for operation and curative irradiation 4)Having measurable disease for RECIST ver. 1.1 5)More than 20 years old and less than 75 years old 6)Performance status: 0-1 7)Life expectancy: over 90 days 8)Adequate organ functions 9)PaO2 >= 70torr or SpO2 >= 95% at room air 10)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Active double cancer 2)Interstitial pneumonitis on chest CT 3)Symptomatic brain metastases 4)Uncontrollable pleural effusion or pericardial effusion 5)Having hemoptysis 6)Having risk factor of bleeding 7)Gastrointestinal ulcer or past history of gastrointestinal perforation 8)Uncontrollable hyper tension 9)Active infectious disease 10)Receiving steroids or immunosuppressants 11)Receiving consecutive oxygen therapy 12)Inadequate period from open surgery 13)Planning open surgery 14)Pregnant or breastfeeding woman 15)History of severe allergy 16)Having other severe complications 17)Patients whose physicians considered as inappropriate for this clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To conclude maximum tolerated dose and recommended phase II dose. | — |
Countries
Japan
Contacts
Public ContactRyo Ko, Takehito Shukuya
Juntendo University Department of Respiratory Medicine
Outcome results
None listed